BACKGROUND: The failing heart is characterized by changes in gene expression. However, the regulatory regions of the genome that drive these gene expression changes have not been well defined in human hearts. METHODS: To define genome-wide enhancer and promoter use in heart failure, cap analysis of gene expression sequencing was applied to 3 healthy and 4 failed human hearts to identify promoter and enhancer regions used in left ventricles. Healthy hearts were derived from donors unused for transplantation and failed hearts were obtained as discarded tissue after transplantation. RESULTS: Cap analysis of gene expression sequencing identified a combined potential for ≈23 000 promoters and ≈5000 enhancers active in human left ventricles. Of these, 17 000 promoters and 1800 enhancers had additional support for their regulatory function. Comparing promoter usage between healthy and failed hearts highlighted promoter shifts which altered aminoterminal protein sequences. Enhancer usage between healthy and failed hearts identified a majority of differentially used heart failure enhancers were intronic and primarily localized within the first intron, revealing this position as a common feature associated with tissue-specific gene expression changes in the heart. CONCLUSIONS: This data set defines the dynamic genomic regulatory landscape underlying heart failure and serves as an important resource for understanding genetic contributions to cardiac dysfunction. Additionally, regulatory changes contributing to heart failure are attractive therapeutic targets for controlling ventricular remodeling and clinical progression.
BACKGROUND: The failing heart is characterized by changes in gene expression. However, the regulatory regions of the genome that drive these gene expression changes have not been well defined in human hearts. METHODS: To define genome-wide enhancer and promoter use in heart failure, cap analysis of gene expression sequencing was applied to 3 healthy and 4 failed human hearts to identify promoter and enhancer regions used in left ventricles. Healthy hearts were derived from donors unused for transplantation and failed hearts were obtained as discarded tissue after transplantation. RESULTS: Cap analysis of gene expression sequencing identified a combined potential for ≈23 000 promoters and ≈5000 enhancers active in human left ventricles. Of these, 17 000 promoters and 1800 enhancers had additional support for their regulatory function. Comparing promoter usage between healthy and failed hearts highlighted promoter shifts which altered aminoterminal protein sequences. Enhancer usage between healthy and failed hearts identified a majority of differentially used heart failure enhancers were intronic and primarily localized within the first intron, revealing this position as a common feature associated with tissue-specific gene expression changes in the heart. CONCLUSIONS: This data set defines the dynamic genomic regulatory landscape underlying heart failure and serves as an important resource for understanding genetic contributions to cardiac dysfunction. Additionally, regulatory changes contributing to heart failure are attractive therapeutic targets for controlling ventricular remodeling and clinical progression.
Authors: Piero Carninci; Albin Sandelin; Boris Lenhard; Shintaro Katayama; Kazuro Shimokawa; Jasmina Ponjavic; Colin A M Semple; Martin S Taylor; Pär G Engström; Martin C Frith; Alistair R R Forrest; Wynand B Alkema; Sin Lam Tan; Charles Plessy; Rimantas Kodzius; Timothy Ravasi; Takeya Kasukawa; Shiro Fukuda; Mutsumi Kanamori-Katayama; Yayoi Kitazume; Hideya Kawaji; Chikatoshi Kai; Mari Nakamura; Hideaki Konno; Kenji Nakano; Salim Mottagui-Tabar; Peter Arner; Alessandra Chesi; Stefano Gustincich; Francesca Persichetti; Harukazu Suzuki; Sean M Grimmond; Christine A Wells; Valerio Orlando; Claes Wahlestedt; Edison T Liu; Matthias Harbers; Jun Kawai; Vladimir B Bajic; David A Hume; Yoshihide Hayashizaki Journal: Nat Genet Date: 2006-04-28 Impact factor: 38.330
Authors: Irina A Sergeeva; Ingeborg B Hooijkaas; Jan M Ruijter; Ingeborg van der Made; Nina E de Groot; Harmen J G van de Werken; Esther E Creemers; Vincent M Christoffels Journal: Development Date: 2016-04-05 Impact factor: 6.868
Authors: Joseph A Wamstad; Jeffrey M Alexander; Rebecca M Truty; Avanti Shrikumar; Fugen Li; Kirsten E Eilertson; Huiming Ding; John N Wylie; Alexander R Pico; John A Capra; Genevieve Erwin; Steven J Kattman; Gordon M Keller; Deepak Srivastava; Stuart S Levine; Katherine S Pollard; Alisha K Holloway; Laurie A Boyer; Benoit G Bruneau Journal: Cell Date: 2012-09-12 Impact factor: 41.582
Authors: Dalit May; Matthew J Blow; Tommy Kaplan; David J McCulley; Brian C Jensen; Jennifer A Akiyama; Amy Holt; Ingrid Plajzer-Frick; Malak Shoukry; Crystal Wright; Veena Afzal; Paul C Simpson; Edward M Rubin; Brian L Black; James Bristow; Len A Pennacchio; Axel Visel Journal: Nat Genet Date: 2011-12-04 Impact factor: 38.330
Authors: Matthias Heinig; Michiel E Adriaens; Sebastian Schafer; Hanneke W M van Deutekom; Elisabeth M Lodder; James S Ware; Valentin Schneider; Leanne E Felkin; Esther E Creemers; Benjamin Meder; Hugo A Katus; Frank Rühle; Monika Stoll; François Cambien; Eric Villard; Philippe Charron; Andras Varro; Nanette H Bishopric; Alfred L George; Cristobal Dos Remedios; Aida Moreno-Moral; Francesco Pesce; Anja Bauerfeind; Franz Rüschendorf; Carola Rintisch; Enrico Petretto; Paul J Barton; Stuart A Cook; Yigal M Pinto; Connie R Bezzina; Norbert Hubner Journal: Genome Biol Date: 2017-09-14 Impact factor: 13.583
Authors: Chukwuemeka G Anene-Nzelu; Mick C J Lee; Wilson L W Tan; Albert Dashi; Roger S Y Foo Journal: Nat Rev Cardiol Date: 2021-08-11 Impact factor: 32.419
Authors: Anthony M Gacita; Dominic E Fullenkamp; Joyce Ohiri; Tess Pottinger; Megan J Puckelwartz; Marcelo A Nobrega; Elizabeth M McNally Journal: Circulation Date: 2021-01-22 Impact factor: 39.918